Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yves Fradet, Joaquim Bellmunt, Ronald De Wit, David J. Vaughn, Jae-Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel A. Climent, Daniel Peter Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stephane Culine, Cora N. Sternberg, Kijoeng Nam, Tara L. Frenkl, Rodolfo F. Perini, Dean F. Bajorin
Institutions: CHU de Québec-Université Laval, Dana-Farber Cancer Institute, Erasmus MC Cancer Institute, University of Pennsylvania Health System, Abramson Cancer Center, Asan Medical Center, University of Ulsan, University of California, San Francisco, Comprehensive Cancer Centers of Nevada, Fundación Instituto Valenciano de Oncología, Yale University, Smilow Cancer Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Radboud University Medical Center, Westmead Hospital, Macquarie University, USC Norris Comprehensive Cancer Center, Hôpital Saint-Louis, Azienda Ospedaliera San Camillo-Forlanini, Merck & Co., Inc., Rahway, NJ, USA (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4239481592